$5.92
▲ +3.3% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice
Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $11
Overview
52-week range
$2.33
$6.79
80% of range
Avg surprise (last 3)
+25.8%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
115%
EM ±26.3% · $6 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.14 | $-0.22 | +36.4% | +6.7% | +0.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.19 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.12 | $-0.17 | +29.4% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.15 | $-0.17 | +11.8% | — | 0.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.17 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.13 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.10 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.11 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | AMC | -$0.17 | -$0.12 | -41.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | — | $9M | $17M | $4M | — | $7M | $7M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-58M | — | $-76M | $-50M | $-63M | — | $-94M | $-93M |
| Net income | $-43M | — | $-57M | $-35M | $-46M | — | $-51M | $-37M |
| EPS (diluted) | $-0.14 | — | $-0.19 | $-0.12 | $-0.15 | — | $-0.17 | $-0.13 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $77M | $129M | $83M | $92M | $159M | $156M | $127M | $148M |
| Inventory | $8M | $6M | — | — | — | — | — | — |
| Total current assets | $665M | $728M | $695M | $742M | $765M | $751M | $743M | $772M |
| Total assets | $1.31B | $1.36B | $1.36B | $1.40B | $1.34B | $1.36B | $1.39B | $1.41B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $369M | $390M | $392M | $395M | $321M | $304M | $315M | $302M |
| Total equity | $938M | $967M | $964M | $1.01B | $1.02B | $1.06B | $1.08B | $1.11B |